First-Line Cemiplimab for Locally Advanced NSCLC: Updated Subgroup Analyses From the EMPOWER-Lung 1 and EMPOWER-Lung 3 Trials
This subgroup analysis supports the clinical benefit of 1L cemiplimab as monotherapy or combined with chemotherapy in patients with unresectable locally advanced NSCLC (not candidates for definitive chemoradiotherapy).
Authors
- Igor Bondarenko (ORCID: https://orcid.org/0000-0002-7071-2471)
- Frank Seebach
- Ewa E. Kalinka
- Miranda Gogishvili (ORCID: https://orcid.org/0000-0002-5143-6379)
- Tamar Melkadze (ORCID: https://orcid.org/0000-0003-0800-6514)
- Ana Baramidze (ORCID: https://orcid.org/0000-0003-3606-3268)
- Ruben G.W. Quek (ORCID: https://orcid.org/0000-0001-9602-3239)
- Pouliot Jean-Francois
- Mustafa Özgüroğlu
- Debra A.G. McIntyre
- Tamta Makharadze
- Konstantin Penkov
- Saadettin Kilickap
- Ahmet Sezer
- Mahmut Gümüş
- Davit Giorgadze
- Eric Kim
Institutions
- Regeneron (United States) (US)
- Medical Center Hospital (US)
- Istanbul University-Cerrahpaşa (TR)
- Istinye University (TR)
- Budgetary Healthcare Institution of Omsk Region Regional Clinical Hospital (RU)
- Polish Mother’s Memorial Hospital Research Institute (PL)
- Istanbul Medeniyet University (TR)
- Dnipro State Medical University (UA)
Publication Details
- Journal
- JTO Clinical and Research Reports
- Published
- 2025-12-22
- DOI
- https://doi.org/10.1016/j.jtocrr.2025.100947
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00